Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because you know what we are going to say — that oh-so-familiar routine of deadlines, meetings, Skype calls, and the like has predictably returned with a vengeance. But what can you do? The world keeps spinning, sometimes faster than we would like. So to cope, yes, we are firing up the coffee kettle to brew cups of stimulation. Our choice today is maple pecan. Feel free to join us. Meanwhile, here are a few tidbits to get you started. Hope all goes well today and, as always, please do keep in touch.

Nearly eight in 10 Americans say the cost of prescription drugs is unreasonable, but with such broad and bipartisan support, why do the odds look grim for Congress to pass significant drug pricing legislation this year? Kaiser Health News asks. Whether the issue is sharing the credit for a legislative victory with the other party or running afoul of the powerful drug maker lobby, neither Democrats nor Republicans are sure the benefits are worth the risks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy